Yahoo Finance host Josh Lipton breaks down the day's top trending stocks and market stories in the Market Minute. AbbVie (ABBV) shares continue to pop in Friday trading after raising its revenue ...

Vertex Pharmaceuticals (VRTX) stock is rising following Food and Drug Administration (FDA) approval of Journavx, a non-opioid ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

The US Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...

Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.

For those who may need relief from pain, Journavx symbolizes not only a new option but also a significant step forward in how we can tackle the challenges of pain management in the 21st century. The ...

Vertex Pharmaceuticals (VRTX) is up more than +4% after receiving FDA approval for its non-opioid analgesic Journavx to treat moderate-to-severe acute pain in adults. LPL Financial Holdings (LPLA) is ...

Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, Intel declines after ...

Introducing Journavx as a Safe Opioid Alternative for Pain Relief"** In a notable development, the FDA has granted approval for Journavx, positioning it as a viable alternative to opioids for pain ...

It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.